Scientists determined the safety and explored efficacy of umbilical cord mesenchymal stem cell infusions in subjects with COVID‐19 scute respiratory distress syndrome. A double‐blind, Phase I/IIa, randomized, controlled trial was performed.
[Stem Cells Translational Medicine]
Lanzoni, G., Linetsky, E., Correa, D., Cayetano, S. M., Alvarez, R. A., Kouroupis, D., Gil, A. A., Poggioli, R., Ruiz, P., Marttos, A. C., Hirani, K., Bell, C. A., Kusack, H., Rafkin, L., Baidal, D., Pastewski, A., Gawri, K., Leñero, C., Mantero, A. M. A., … Ricordi, C. (n.d.). Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. STEM CELLS Translational Medicine, n/a(n/a). https://doi.org/https://doi.org/10.1002/sctm.20-0472 Cite
0